CompletedPhase 2

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

United States32 participantsStarted 2015-07

Plain-language summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of different doses of ALLN 177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and recurrent kidney stones.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of enteric or idiopathic hyperoxaluria and at least one kidney stone within the past 2 years * Hyperoxaluria at screening * May be taking drugs for the prevention of stone disease Exclusion Criteria: * Hyperuricosuria * Glomerular filtration rate \< 55 mL/min/1.73m2 * Hypercalcemia or hypothyroidism * Obstructive uropathy, chronic urosepsis, renal failure, renal tubular acidosis, primary hyperparathyroidism, primary hyperoxaluria, pure uric acid and cystine stones, and/or medullary sponge kidney * Treatment with cholestyramine * Average daily dietary intake of oxalate \<75 mg per day

What they're measuring

Mean urinary oxalate excretion (mg/24 h) following treatment

Timeframe: on 7 days of treatment

Trial details

NCT IDNCT02503345

SponsorAllena Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-08

View on ClinicalTrials.gov More Secondary Hyperoxaluria trials